Literature DB >> 7559865

Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.

A R Hermus1, A G Smals, L M Swinkels, D A Huysmans, G F Pieters, C F Sweep, F H Corstens, P W Kloppenborg.   

Abstract

We measured bone mineral density (BMD) using dual-energy x-ray absorptiometry in 20 patients with Cushing's syndrome (CS) (14 pre- and 2 postmenopausal women, 4 men) before and in 18 of them also at regular intervals after surgical cure (median duration of follow-up, 36 months). In addition, in the premenopausal women with CS, fasting blood samples and 2-h fasting urine samples for measurement of biochemical parameters of bone and collagen metabolism were collected before and in 9 of them also at regular intervals during the first 2 yr after surgery. Marked osteopenia was present in most patients with active CS (Z-scores: lumbar spine -1.45 +/- 1.44 and femoral neck -1.50 +/- 1.02; mean +/- SD). No consistent change in BMD was observed at 3 and 6 months after surgery. Thereafter BMD increased considerably in almost all patients. For the 15 patients with a follow-up of at least 1 yr, Z-scores at the last evaluation were -0.65 +/- 1.27 for the lumbar spine and -0.98 +/- 1.02 for the femoral neck (both P < 0.002 compared with pretreatment values). In the premenopausal patients, the increase in BMD both in the lumbar spine and in the femoral neck at 24 months was inversely correlated with age (r = -0.733, P < 0.03, and r = -0.667, P < 0.05, respectively). Serum levels of osteocalcin, bone alkaline phosphatase, carboxyterminal propeptide of type I procollagen, aminoterminal propeptide of type III procollagen, and the cross-linked telopeptide of type I collagen were not significantly different between the group of 14 premenopausal patients with active CS and a control group of 18 age-matched healthy premenopausal women. However, the urinary hydroxyproline/creatinine ratio was significantly higher in patients with CS (24.6 +/- 9.6 vs. 16.2 +/- 3.5 mumol/mmol, P < 0.01). In all 9 premenopausal patients, serum levels of osteocalcin increased considerably between 0 and 3 months (from 1.04 +/- 0.20 to 3.82 +/- 0.30 nmol/L) (mean +/- SEM, P < 0.0001), indicating a prompt increase of osteoblast activity. Also serum levels of carboxyterminal propeptide of type I procollagen, aminoterminal propeptide of type III procollagen, and cross-linked telopeptide of type I collagen, and the urinary hydroxyproline/creatinine ratio increased significantly between 0 and 3 months. Thereafter these levels decreased gradually. We conclude that marked osteopenia in the lumbar spine and femoral neck is present in most patients with active Cushing's syndrome.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559865     DOI: 10.1210/jcem.80.10.7559865

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

1.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

2.  Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study.

Authors:  Akiko Kawamata; Masatoshi Iihara; Takahiro Okamoto; Takao Obara
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

3.  Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid.

Authors:  H Kaji; M Yamauchi; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-11-14       Impact factor: 4.507

4.  Lactating Ctcgrp nulls lose twice the normal bone mineral content due to fewer osteoblasts and more osteoclasts, whereas bone mass is fully restored after weaning in association with up-regulation of Wnt signaling and other novel genes.

Authors:  Jillian N Collins; Beth J Kirby; Janine P Woodrow; Robert F Gagel; Clifford J Rosen; Natalie A Sims; Christopher S Kovacs
Journal:  Endocrinology       Date:  2013-03-05       Impact factor: 4.736

Review 5.  Cushing's syndrome and bone.

Authors:  Tatiana Mancini; Mauro Doga; Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

6.  Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease.

Authors:  S Scommegna; J P Greening; H L Storr; K M Davies; N J Shaw; J P Monson; A B Grossman; M O Savage
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

7.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

8.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

9.  Spine abnormalities and damage in patients cured from Cushing's disease.

Authors:  A Faggiano; R Pivonello; M Filippella; C Di Somma; F Orio; G Lombard; A Colao
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

Review 10.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.